Methodological issues in primary prevention trials for neurodegenerative dementia. Tekijä Andrieu, S, Coley, N, Aisen, P, Carrillo, M, DeKosky, S, Durga, J, Fillit, H, Frisoni, G, Froelich, L, Gauthier, S, Jones, R, Jönsson, L, Khachaturian, Z, Morris, J, Orgogozo, J, Ousset, P, Robert, P, Salmon, E, Sampaio, C, Verhey, F, Wilcock, G, Vellas, B

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Tekijä Vellas, B, Carrillo, M, Sampaio, C, Brashear, H, Siemers, E, Hampel, H, Schneider, L, Weiner, M, Doody, R, Khachaturian, Z, Cedarbaum, J, Grundman, M, Broich, K, Giacobini, E, Dubois, B, Sperling, R, Wilcock, G, Fox, N, Scheltens, P, Touchon, J, Hendrix, S, Andrieu, S, Aisen, P